Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension

N-terminal pro-brain natriuretic peptide (NT-proBNP) is a marker of neurohormonal activation that is useful in the diagnosis and prognosis of various forms of pulmonary arterial hypertension (PAH). We sought to characterise and compare NT-proBNP in a cohort of PAH related to systemic sclerosis (PAH-SSc) and idiopathic PAH (IPAH) patients. NT-proBNP levels, collected from PAH-SSc and IPAH patients followed prospectively, were compared and correlated with haemodynamic variables. Cox proportional hazard models were created to assess the predictive value of NT-proBNP. 98 patients (55 PAH-SSc, 43 IPAH) were included. Haemodynamics were similar, except for lower mean pulmonary arterial pressure in PAH-SSc. NT-proBNP levels were significantly higher in PAH-SSc (3,419±3,784 versus 1,393±1,633 pg·mL−1; p<0.01) and were more closely related to haemodynamics in PAH-SSc than IPAH. 28 patients died. NT-proBNP predicted survival (hazard ratio (HR) 3.18; p<0.01) in the overall cohort; however, when stratified by group, predicted survival only in PAH-SSc (HR 3.07, p<0.01 versus 2.02, p = 0.29 in IPAH). This is the first description showing NT-proBNP levels are 1) significantly higher in PAH-SSc than IPAH despite less severe haemodynamic perturbations, and 2) stronger predictors of survival in PAH-SSc, suggesting that neurohormonal regulation may differ between PAH-SSc and IPAH. Future studies to define pertinent mechanisms are warranted.

[1]  A. Zaiman,et al.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. , 2009, Arthritis and rheumatism.

[2]  P. Corris,et al.  Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. , 2009, American journal of respiratory and critical care medicine.

[3]  P. Hassoun,et al.  Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[4]  B. Dijkmans,et al.  Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension , 2008, European Respiratory Journal.

[5]  W. Lehmacher,et al.  The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement , 2008, Rheumatology.

[6]  F. Boomsma,et al.  NT-pro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity. , 2008, Journal of applied physiology.

[7]  M. Irwin,et al.  Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists. , 2008, Arthritis and rheumatism.

[8]  M. Humbert,et al.  Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis , 2007, Annals of the rheumatic diseases.

[9]  G. Giannakoulas,et al.  N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension , 2008, Clinical Rheumatology.

[10]  A. Maisel,et al.  State-of-the-Art PaperNatriuretic Peptides , 2007 .

[11]  R. Naeije,et al.  Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? , 2007, European Respiratory Journal.

[12]  J. Bronzwaer,et al.  Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. , 2007, Chest.

[13]  J. Foster,et al.  NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension , 2007, European Respiratory Journal.

[14]  B. Hartmann,et al.  N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. , 2007, Chest.

[15]  P. Hassoun,et al.  N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[16]  M. Hoeper,et al.  Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. , 2007, American heart journal.

[17]  M. Humbert,et al.  NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. , 2007, Respiratory medicine.

[18]  J. Marcus,et al.  NT-proBNP reflects right ventricular structure and function in pulmonary hypertension , 2006, European Respiratory Journal.

[19]  G. Hutchins,et al.  A case–control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma) , 2006, Gut.

[20]  J. Bronzwaer,et al.  Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension , 2006, Heart.

[21]  T. Abraham,et al.  Tricuspid annular displacement predicts survival in pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[22]  J. Krishnan,et al.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. , 2006, Arthritis and rheumatism.

[23]  J. Kao,et al.  Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[24]  C. Denton,et al.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[25]  A. Torbicki,et al.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[26]  M. Baron,et al.  Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. , 2006, Chest.

[27]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[28]  M. Drazner,et al.  Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study , 2005, Circulation.

[29]  S. Rantapää-Dahlqvist,et al.  Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. , 2005, Chest.

[30]  J. Lima,et al.  The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). , 2005, Arthritis and rheumatism.

[31]  R. Souza,et al.  Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension , 2005, Current medical research and opinion.

[32]  J. Bartunek,et al.  Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[33]  M. Vogeser,et al.  Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. , 2004, American journal of respiratory and critical care medicine.

[34]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[35]  M. LeWinter,et al.  Increased Atrial and Brain Natriuretic Peptides in Adults With Cyanotic Congenital Heart Disease: Enhanced Understanding of the Relationship Between Hypoxia and Natriuretic Peptide Secretion , 2004, Circulation.

[36]  D. Borderie,et al.  N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. , 2003, Arthritis and rheumatism.

[37]  Douglas L Mann,et al.  Stress-activated cytokines and the heart: from adaptation to maladaptation. , 2003, Annual review of physiology.

[38]  A. Holmes,et al.  Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2003, Respiratory medicine.

[39]  E. Bonfá,et al.  Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. , 2003, Journal of cardiac failure.

[40]  S. Kimmel,et al.  Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.

[41]  Pedro Lozano.  Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[42]  J. Burnett,et al.  Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases , 2002, Circulation research.

[43]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[44]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[45]  A. Nicholson,et al.  Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. , 2001, Radiology.

[46]  Y Lecarpentier,et al.  Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. , 2001, Journal of the American College of Cardiology.

[47]  G. Valentini,et al.  Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension , 2000, Annals of the rheumatic diseases.

[48]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[49]  I. Hausmanowa-Petrusewicz,et al.  Sympathetic Skin Response in Scleroderma, Scleroderma Overlap Syndromes and Inflammatory Myopathies , 1999, Clinical Rheumatology.

[50]  K. Shroyer,et al.  Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[51]  M. Humbert,et al.  Primary pulmonary hypertension associated with the use of fenfluramine derivatives. , 1998, Chest.

[52]  H. Itoh,et al.  Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. , 1998, Journal of cardiovascular pharmacology.

[53]  R. Sjogren.  Gastrointestinal features of scleroderma. , 1996, Current opinion in rheumatology.

[54]  M. Jayson,et al.  Autonomic neuropathy in systemic sclerosis. , 1988, Annals of the rheumatic diseases.

[55]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[56]  B. Amor,et al.  Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. , 1986, The New England journal of medicine.

[57]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[58]  P. Clayton,et al.  Lung volumes in healthy nonsmoking adults. , 1982, Bulletin europeen de physiopathologie respiratoire.

[59]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[60]  A H Morris,et al.  Standardized single breath normal values for carbon monoxide diffusing capacity. , 2015, The American review of respiratory disease.

[61]  J. S. Janicki,et al.  Myocardial oxygen consumption: the role of wall force and shortening. , 1977, The American journal of physiology.